Hifuture Technology(SZ:002168)2025-01-17 11:40Financial Performance - The company expects a net loss attributable to shareholders of between 130 million and 180 million yuan for the year 2024, compared to a profit of 1.8973 million yuan in the same period last year [3]. - Operating revenue is projected to be between 200 million and 290 million yuan, down from 254.1623 million yuan in the previous year [3]. - The company reported a projected loss of 140 million to 190 million yuan for net profit after deducting non-recurring items, compared to a loss of 121.1296 million yuan last year [3]. - The basic earnings per share are expected to be a loss of between 0.1658 yuan and 0.2295 yuan, compared to earnings of 0.0024 yuan per share last year [3]. - The company's equity attributable to shareholders is projected to be between -40 million and -21 million yuan, down from 17.541 million yuan in the previous year [3]. Business Strategy - The company plans to expand its business into the biopharmaceutical sector by acquiring 51% of Chongqing Ruien Pharmaceutical Co., Ltd. for 47 million yuan, which will become a subsidiary [7]. - The company will focus on enhancing its core smart manufacturing business and increasing market expansion efforts to improve revenue and profitability [7]. - The company plans to strengthen production management and cost control to gradually improve operational quality [7]. Non-Recurring Items - The company anticipates a non-recurring loss impact of approximately 16 million to 20 million yuan on net profit, mainly due to performance compensation and litigation provisions [7]. Regulatory Risks - The company will disclose detailed financial data in the 2024 annual report, and there is a risk of delisting if certain financial thresholds are not met [9].